Drug intelligence / Profile preview

GC001 oncolytic vaccinia virus

Development stage: Phase 1
Lead developer: Hangzhou Gongchu Biotechnology
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

GC001 is an oncolytic vaccinia virus developed by Hangzhou Gongchu Biotechnology. It functions as a STRIP1 (striatin interacting protein 1) inhibitor. As an oncolytic virus therapy, it is designed to selectively infect and destroy cancer cells while also potentially stimulating an immune response against the tumor. The drug is currently being investigated in Phase 1 clinical trials for various advanced solid tumors, including high-grade glioma, breast cancer, and recurrent or progressive gliomas of the brain.

Other names: GC001溶瘤痘苗病毒

Targets

STRIP1 (Striatin-interacting protein 1)

Beyond the preview

Go deeper on GC001 oncolytic vaccinia virus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC001 oncolytic vaccinia virus.

Explore the full profile